GEM
BOLD

Global Endowment Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Global Endowment Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-581,488
Closed -$16.3M – 112
2019
Q3 		$16.3M Buy
581,488
+131,523
+29% +$4.49M 1.43% 9
2019
Q2 		$17M Buy
449,965
+58,384
+15% +$2.24M 1.64% 10
2019
Q1 		$15.3M Sell
391,581
-110,758
-22% -$3.18M 2.16% 6
2018
Q4 		$10.7M Buy
+502,339
New +$13M 2.29% 7

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Global Endowment Management's BOLD Position: Q4 2019 in Review

Global Endowment Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 581,488 shares — an estimated $16.3M sold.

Global Endowment Management first reported a position in BOLD in Q4 2018 and held it in 4 quarters. The position peaked at $17M in Q2 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Global Endowment Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Global Endowment Management sold 581,488 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $16.3M.
  • Global Endowment Management first reported a position in Audentes Therapeutics, Inc in Q4 2018 and held it in 4 quarters.
  • Global Endowment Management's Audentes Therapeutics, Inc position peaked at $17M in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Global Endowment Management's 13F filing for Q4 2019, filed 12 Feb 2020.